NEUROTECH INTERNATIONAL LIMITED - Announcements

7.69%

1.4¢

Market Cap $14.69M

Healthcare Biotechnology

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical... Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Little Green Pharma (ASX:LGP) to benefit as Denmark commits to cannabis pilot program.

Announcements

Filter Results

All Price Sensitive Only

NTI	Positive Top-Line Rett Syndrome Clinical Trial Results	PRICE SENSITIVE	17/04/24	200.12KB	Share
NTI	Phase II/III ASD Trial Successfully Meets Primary Endpoint	PRICE SENSITIVE	17/04/24	361.07KB	Share
NTI	Investor Webinar on Clinical Trial Results		16/04/24	98.91KB	Share
NTI	Trading Halt	PRICE SENSITIVE	15/04/24	141.44KB	Share
NTI	Proposed issue of securities - NTI		10/04/24	19.39KB	Share
NTI	Strategic Partnership with Fenix Innovation Group		10/04/24	196.39KB	Share
NTI	Last Patient Completes Treatment in NTIASD2 Clinical Trial	PRICE SENSITIVE	10/04/24	183.31KB	Share
NTI	Change in substantial holding		27/03/24	289.69KB	Share
NTI	Appointment of Joint Company Secretary		21/03/24	76.78KB	Share
NTI	Neurotech Presentation at NWR Virtual Healthcare Conference		21/03/24	2.52MB	Share
NTI	Neurotech to present at NWR Virtual Healthcare Conference		19/03/24	98.59KB	Share
NTI	Secondary Trading Notice		15/03/24	91.99KB	Share
NTI	Notification regarding unquoted securities - NTI		15/03/24	14.66KB	Share
NTI	Application for quotation of securities - NTI		15/03/24	15.68KB	Share
NTI	NTI to Present at Spark Plus Conference in Singapore		13/03/24	2.59MB	Share
NTI	Rett Syndrome Patients to Receive NTI164 for 52 Weeks	PRICE SENSITIVE	13/03/24	180.94KB	Share
NTI	Notification of cessation of securities - NTI		12/03/24	14.65KB	Share
NTI	Secondary Trading Notice		11/03/24	91.98KB	Share
NTI	Notification regarding unquoted securities - NTI		08/03/24	14.99KB	Share
NTI	Application for quotation of securities - NTI		08/03/24	15.9KB	Share
NTI	Initial ESG Report		27/02/24	1.8MB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	27/02/24	814.41KB	Share
NTI	Investor Presentation		21/02/24	2.39MB	Share
NTI	PANDAS/PANS Patients Show Continued Clinical Improvement	PRICE SENSITIVE	21/02/24	325.1KB	Share
NTI	Secondary Trading Notice		14/02/24	93.56KB	Share
NTI	Notification regarding unquoted securities - NTI		14/02/24	14.99KB	Share
NTI	Application for quotation of securities - NTI		14/02/24	15.91KB	Share
NTI	Neurotech Receives Additional HREC Approval in Autism	PRICE SENSITIVE	13/02/24	114.1KB	Share
NTI	ASD Phase I/II Patients Exceed Treatment Beyond 90 Weeks		07/02/24	130.25KB	Share
NTI	Amended Change of Director's Interest Notice		30/01/24	233.81KB	Share
NTI	Change of Director's Interest Notice		30/01/24	150.24KB	Share
NTI	NTI Receives HREC Approval for Cerebral Palsy Trial	PRICE SENSITIVE	29/01/24	179.92KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/01/24	583.12KB	Share
NTI	Secondary Trading Notice		22/01/24	91.57KB	Share
NTI	Application for quotation of securities - NTI		22/01/24	25.64KB	Share
NTI	Notification regarding unquoted securities - NTI		17/01/24	28.33KB	Share
NTI	Secondary Trading Notice		19/12/23	91.77KB	Share
NTI	Application for quotation of securities - NTI		19/12/23	24.91KB	Share
NTI	Phase II/III Autism Clinical Trial Completes Recruitment	PRICE SENSITIVE	19/12/23	178.77KB	Share
NTI	Change in substantial holding		05/12/23	291.25KB	Share
NTI	HREC Approval to Extend Phase II/III ASD Trial to Adults	PRICE SENSITIVE	04/12/23	175.52KB	Share
NTI	Change of Director's Interest Notice x 2		01/12/23	329.86KB	Share
NTI	Application for quotation of securities - NTI		30/11/23	24.93KB	Share
NTI	Investor Presentation		22/11/23	2.34MB	Share
NTI	New Constitution		15/11/23	603.29KB	Share
NTI	Results of Meeting		15/11/23	103.44KB	Share
NTI	2023 Annual General Meeting Presentation		15/11/23	1.89MB	Share
NTI	Chairman's Address to 2023 Annual General Meeting		15/11/23	111.09KB	Share
NTI	Neurotech Receives $3.17 Million R&D Tax Incentive Refund	PRICE SENSITIVE	14/11/23	105.98KB	Share
NTI	Q&A on Phase I/II PANDAS/PANS Clinical Trial Results		01/11/23	169.14KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/10/23	396.35KB	Share
NTI	Notice of Quarterly Investor Conference Call		24/10/23	101.25KB	Share
NTI	Notice of Annual General Meeting/Proxy Form		16/10/23	626.33KB	Share
NTI	Investor Presentation - PANDAS/PANS Clinical Trials Results		06/10/23	1.58MB	Share
NTI	Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint	PRICE SENSITIVE	06/10/23	202.18KB	Share
NTI	Trading Halt	PRICE SENSITIVE	04/10/23	503.7KB	Share
NTI	Completion of Patient Recruitment in NTIRTT1 Clinical Trial	PRICE SENSITIVE	26/09/23	186.34KB	Share
NTI	Annual Report (Typeset)		22/09/23	6.67MB	Share
NTI	Secondary Trading Notice		18/09/23	93.51KB	Share
NTI	Application for quotation of securities - NTI		18/09/23	25.51KB	Share
NTI	Proposed issue of securities - NTI		15/09/23	24.56KB	Share
NTI	Clinician Briefing Presentation and Webcast		15/09/23	1.78MB	Share
NTI	Proposed issue of securities - NTI		15/09/23	31.63KB	Share
NTI	Appointment of Corporate Advisor		15/09/23	93.81KB	Share
NTI	Upcoming Clinician Briefing		11/09/23	161.9KB	Share
NTI	Last Patient Completes Treatment in NTIPANS1 Clinical Trial	PRICE SENSITIVE	31/08/23	141.88KB	Share
NTI	Appendix 4G and Corporate Governance Statement		30/08/23	375.23KB	Share
NTI	Appendix 4E & Annual Report	PRICE SENSITIVE	30/08/23	1.16MB	Share
NTI	Application for quotation of securities - NTI		08/08/23	24.86KB	Share
NTI	Proposed issue of securities - NTI		04/08/23	24.68KB	Share
NTI	Disclosure Document		04/08/23	310.97KB	Share
NTI	First Patient Treated in Rett Syndrome Clinical Trial	PRICE SENSITIVE	01/08/23	181.29KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/07/23	321.97KB	Share
NTI	Notice of Quarterly Investor Conference Call		19/07/23	138.69KB	Share
NTI	NTI Receives HREC Approval for Rett Syndrome Clinical Trial	PRICE SENSITIVE	10/07/23	213.2KB	Share
NTI	Notification of cessation of securities - NTI		30/06/23	22.47KB	Share
NTI	Notification regarding unquoted securities - NTI		28/06/23	43.13KB	Share
NTI	NTI to Present at Rett Syndrome Foundation Meeting		05/06/23	120.49KB	Share
NTI	Results of Meeting		01/06/23	102.52KB	Share
NTI	NTI Granted 2 Year Extension of Treatment for ASD Patients	PRICE SENSITIVE	31/05/23	188.33KB	Share
NTI	NTI granted HREC Approval for PANDAS/PANS Trial Extension	PRICE SENSITIVE	30/05/23	178.8KB	Share
NTI	Notification of cessation of securities - NTI		16/05/23	21.67KB	Share
NTI	NTI Completes Recruitment in PANDAS/PANS Clinical Trial	PRICE SENSITIVE	03/05/23	138.62KB	Share
NTI	Proposed issue of securities - NTI		01/05/23	43.72KB	Share
NTI	Notification of cessation of securities - NTI		01/05/23	24.62KB	Share
NTI	Notice of General Meeting/Proxy Form		01/05/23	901.29KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/04/23	335.94KB	Share
NTI	Notice of Quarterly Investor Conference Call		26/04/23	101.37KB	Share
NTI	Neurotech to Present at NWR Virtual Healthcare Conference		20/03/23	100.11KB	Share
NTI	Investor Presentation		20/03/23	2.47MB	Share
NTI	NTI to Launch Phase II Clinical Trial in Rett Syndrome	PRICE SENSITIVE	20/03/23	199.04KB	Share
NTI	Investor Conference Call - 52 Week Autism Study Results		17/03/23	113.7KB	Share
NTI	Investor Presentation		17/03/23	2.35MB	Share
NTI	Phase I/II ASD Clinical Trials Results at 52 Weeks	PRICE SENSITIVE	17/03/23	360.83KB	Share
NTI	Trading Halt	PRICE SENSITIVE	15/03/23	499.87KB	Share
NTI	Notification of cessation of securities - NTI		01/03/23	22.76KB	Share
NTI	Notification regarding unquoted securities - NTI		28/02/23	30.23KB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	28/02/23	476.67KB	Share
NTI	First Patient Treated in Phase I/II PANDAS/PANS Trial	PRICE SENSITIVE	16/02/23	170.25KB	Share
NTI	Approval for Additional Phase I/II ASD Trial Extension	PRICE SENSITIVE	14/02/23	170.33KB	Share

NTI Positive Top-Line Rett Syndrome Clinical Trial Results
17/04/24	PRICE SENSITIVE	200.12KB	Share
NTI Phase II/III ASD Trial Successfully Meets Primary Endpoint
17/04/24	PRICE SENSITIVE	361.07KB	Share
NTI Investor Webinar on Clinical Trial Results
16/04/24		98.91KB	Share
NTI Trading Halt
15/04/24	PRICE SENSITIVE	141.44KB	Share
NTI Proposed issue of securities - NTI
10/04/24		19.39KB	Share
NTI Strategic Partnership with Fenix Innovation Group
10/04/24		196.39KB	Share
NTI Last Patient Completes Treatment in NTIASD2 Clinical Trial
10/04/24	PRICE SENSITIVE	183.31KB	Share
NTI Change in substantial holding
27/03/24		289.69KB	Share
NTI Appointment of Joint Company Secretary
21/03/24		76.78KB	Share
NTI Neurotech Presentation at NWR Virtual Healthcare Conference
21/03/24		2.52MB	Share
NTI Neurotech to present at NWR Virtual Healthcare Conference
19/03/24		98.59KB	Share
NTI Secondary Trading Notice
15/03/24		91.99KB	Share
NTI Notification regarding unquoted securities - NTI
15/03/24		14.66KB	Share
NTI Application for quotation of securities - NTI
15/03/24		15.68KB	Share
NTI NTI to Present at Spark Plus Conference in Singapore
13/03/24		2.59MB	Share
NTI Rett Syndrome Patients to Receive NTI164 for 52 Weeks
13/03/24	PRICE SENSITIVE	180.94KB	Share
NTI Notification of cessation of securities - NTI
12/03/24		14.65KB	Share
NTI Secondary Trading Notice
11/03/24		91.98KB	Share
NTI Notification regarding unquoted securities - NTI
08/03/24		14.99KB	Share
NTI Application for quotation of securities - NTI
08/03/24		15.9KB	Share
NTI Initial ESG Report
27/02/24		1.8MB	Share
NTI Appendix 4D and Half Year Accounts
27/02/24	PRICE SENSITIVE	814.41KB	Share
NTI Investor Presentation
21/02/24		2.39MB	Share
NTI PANDAS/PANS Patients Show Continued Clinical Improvement
21/02/24	PRICE SENSITIVE	325.1KB	Share
NTI Secondary Trading Notice
14/02/24		93.56KB	Share
NTI Notification regarding unquoted securities - NTI
14/02/24		14.99KB	Share
NTI Application for quotation of securities - NTI
14/02/24		15.91KB	Share
NTI Neurotech Receives Additional HREC Approval in Autism
13/02/24	PRICE SENSITIVE	114.1KB	Share
NTI ASD Phase I/II Patients Exceed Treatment Beyond 90 Weeks
07/02/24		130.25KB	Share
NTI Amended Change of Director's Interest Notice
30/01/24		233.81KB	Share
NTI Change of Director's Interest Notice
30/01/24		150.24KB	Share
NTI NTI Receives HREC Approval for Cerebral Palsy Trial
29/01/24	PRICE SENSITIVE	179.92KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
24/01/24	PRICE SENSITIVE	583.12KB	Share
NTI Secondary Trading Notice
22/01/24		91.57KB	Share
NTI Application for quotation of securities - NTI
22/01/24		25.64KB	Share
NTI Notification regarding unquoted securities - NTI
17/01/24		28.33KB	Share
NTI Secondary Trading Notice
19/12/23		91.77KB	Share
NTI Application for quotation of securities - NTI
19/12/23		24.91KB	Share
NTI Phase II/III Autism Clinical Trial Completes Recruitment
19/12/23	PRICE SENSITIVE	178.77KB	Share
NTI Change in substantial holding
05/12/23		291.25KB	Share
NTI HREC Approval to Extend Phase II/III ASD Trial to Adults
04/12/23	PRICE SENSITIVE	175.52KB	Share
NTI Change of Director's Interest Notice x 2
01/12/23		329.86KB	Share
NTI Application for quotation of securities - NTI
30/11/23		24.93KB	Share
NTI Investor Presentation
22/11/23		2.34MB	Share
NTI New Constitution
15/11/23		603.29KB	Share
NTI Results of Meeting
15/11/23		103.44KB	Share
NTI 2023 Annual General Meeting Presentation
15/11/23		1.89MB	Share
NTI Chairman's Address to 2023 Annual General Meeting
15/11/23		111.09KB	Share
NTI Neurotech Receives $3.17 Million R&D Tax Incentive Refund
14/11/23	PRICE SENSITIVE	105.98KB	Share
NTI Q&A on Phase I/II PANDAS/PANS Clinical Trial Results
01/11/23		169.14KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
27/10/23	PRICE SENSITIVE	396.35KB	Share
NTI Notice of Quarterly Investor Conference Call
24/10/23		101.25KB	Share
NTI Notice of Annual General Meeting/Proxy Form
16/10/23		626.33KB	Share
NTI Investor Presentation - PANDAS/PANS Clinical Trials Results
06/10/23		1.58MB	Share
NTI Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint
06/10/23	PRICE SENSITIVE	202.18KB	Share
NTI Trading Halt
04/10/23	PRICE SENSITIVE	503.7KB	Share
NTI Completion of Patient Recruitment in NTIRTT1 Clinical Trial
26/09/23	PRICE SENSITIVE	186.34KB	Share
NTI Annual Report (Typeset)
22/09/23		6.67MB	Share
NTI Secondary Trading Notice
18/09/23		93.51KB	Share
NTI Application for quotation of securities - NTI
18/09/23		25.51KB	Share
NTI Proposed issue of securities - NTI
15/09/23		24.56KB	Share
NTI Clinician Briefing Presentation and Webcast
15/09/23		1.78MB	Share
NTI Proposed issue of securities - NTI
15/09/23		31.63KB	Share
NTI Appointment of Corporate Advisor
15/09/23		93.81KB	Share
NTI Upcoming Clinician Briefing
11/09/23		161.9KB	Share
NTI Last Patient Completes Treatment in NTIPANS1 Clinical Trial
31/08/23	PRICE SENSITIVE	141.88KB	Share
NTI Appendix 4G and Corporate Governance Statement
30/08/23		375.23KB	Share
NTI Appendix 4E & Annual Report
30/08/23	PRICE SENSITIVE	1.16MB	Share
NTI Application for quotation of securities - NTI
08/08/23		24.86KB	Share
NTI Proposed issue of securities - NTI
04/08/23		24.68KB	Share
NTI Disclosure Document
04/08/23		310.97KB	Share
NTI First Patient Treated in Rett Syndrome Clinical Trial
01/08/23	PRICE SENSITIVE	181.29KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
26/07/23	PRICE SENSITIVE	321.97KB	Share
NTI Notice of Quarterly Investor Conference Call
19/07/23		138.69KB	Share
NTI NTI Receives HREC Approval for Rett Syndrome Clinical Trial
10/07/23	PRICE SENSITIVE	213.2KB	Share
NTI Notification of cessation of securities - NTI
30/06/23		22.47KB	Share
NTI Notification regarding unquoted securities - NTI
28/06/23		43.13KB	Share
NTI NTI to Present at Rett Syndrome Foundation Meeting
05/06/23		120.49KB	Share
NTI Results of Meeting
01/06/23		102.52KB	Share
NTI NTI Granted 2 Year Extension of Treatment for ASD Patients
31/05/23	PRICE SENSITIVE	188.33KB	Share
NTI NTI granted HREC Approval for PANDAS/PANS Trial Extension
30/05/23	PRICE SENSITIVE	178.8KB	Share
NTI Notification of cessation of securities - NTI
16/05/23		21.67KB	Share
NTI NTI Completes Recruitment in PANDAS/PANS Clinical Trial
03/05/23	PRICE SENSITIVE	138.62KB	Share
NTI Proposed issue of securities - NTI
01/05/23		43.72KB	Share
NTI Notification of cessation of securities - NTI
01/05/23		24.62KB	Share
NTI Notice of General Meeting/Proxy Form
01/05/23		901.29KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
27/04/23	PRICE SENSITIVE	335.94KB	Share
NTI Notice of Quarterly Investor Conference Call
26/04/23		101.37KB	Share
NTI Neurotech to Present at NWR Virtual Healthcare Conference
20/03/23		100.11KB	Share
NTI Investor Presentation
20/03/23		2.47MB	Share
NTI NTI to Launch Phase II Clinical Trial in Rett Syndrome
20/03/23	PRICE SENSITIVE	199.04KB	Share
NTI Investor Conference Call - 52 Week Autism Study Results
17/03/23		113.7KB	Share
NTI Investor Presentation
17/03/23		2.35MB	Share
NTI Phase I/II ASD Clinical Trials Results at 52 Weeks
17/03/23	PRICE SENSITIVE	360.83KB	Share
NTI Trading Halt
15/03/23	PRICE SENSITIVE	499.87KB	Share
NTI Notification of cessation of securities - NTI
01/03/23		22.76KB	Share
NTI Notification regarding unquoted securities - NTI
28/02/23		30.23KB	Share
NTI Appendix 4D and Half Year Accounts
28/02/23	PRICE SENSITIVE	476.67KB	Share
NTI First Patient Treated in Phase I/II PANDAS/PANS Trial
16/02/23	PRICE SENSITIVE	170.25KB	Share
NTI Approval for Additional Phase I/II ASD Trial Extension
14/02/23	PRICE SENSITIVE	170.33KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.4¢		Change 0.001(7.69%)		Mkt cap ! $14.69M

Open	High	Low	Value	Volume
1.3¢	1.4¢	1.3¢	$4.026K	307.2K

Buyers (Bids)

No.	Vol.	Price($)
1	1917576	1.3¢

Sellers (Offers)

Price($)	Vol.	No.
1.4¢	505017	5

View Market Depth

No.	Vol.	Price($)
1	1917576	0.013
11	3680644	0.012
10	2248075	0.011
8	2120000	0.010
2	159000	0.009

Price($)	Vol.	No.
0.014	505017	5
0.015	1025224	4
0.016	689340	9
0.017	268623	2
0.018	563001	4

Last trade - 16.10pm 29/08/2025 (20 minute delay)

NTI (ASX) Chart

NEUROTECH INTERNATIONAL LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories